Neurocrine biosciences announces initiation of phase 1 clinical study evaluating nbi-1140675, a second-generation vmat2 inhibitor, in healthy adults

San diego , march 5, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the initiation of a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound nbi-1140675 in healthy adult participants. nbi-1140675 is an investigational, oral, selective second-generation small molecule inhibitor of the vesicular monoamine transporter 2 (vmat2) in development for the potential treatment of certain neurological and neuropsychiatric conditions.
NBIX Ratings Summary
NBIX Quant Ranking